News
BLCM
--
0.00%
--
Wells Fargo: These 2 Stocks Could Deliver Triple-Digit Wins
Was the recent market volatility just a fake out? After notching an all-time high on September 2, fears related to overheated valuations spurred a rapid correction, marking the first material correction of the current bull market. However, this doesn’t mean the bears have been vindicated, so says Wells
TipRanks · 4d ago
Marinus Pharmaceuticals, Plus Therapeutics among healthcare gainers, Nano-X Imaging, Vaxart lead losers
Gainers: Marinus Pharmaceuticals (MRNS) +83%, Plus Therapeutics (PSTV) +24%, Inovio Pharmaceuticals (INO) +21%, Arbutus Biopharma ABUS +15%, Bellicum Pharmaceuticals (BLCM) +15%.Losers: Nano-X Imaging (NNOX) -24%, Vaxart (VXRT) -14%, Cassava Sciences (SAVA) -14%, 89bio, Inc. (ETNB) -12%, Replimune Group, Inc. (REPL) -8%.
Seekingalpha · 09/15 15:02
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
HOUSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that management will participate in two upcoming virtual investor conferences. Conference Details:Wells Fargo 2020
GlobeNewswire · 09/02 12:30
Bellicum Reports Second Quarter 2020 Financial Results and Provides Operational Update
Received FDA IND clearance to initiate Phase 1/2 clinical trial for BPX-603 for HER2+ solid tumors Initial data for BPX-601 cohort 5C to be presented at a medical meeting by the end of 2020Management to host conference call and webcast today at 5 p.m. ET / 2
GlobeNewswire · 08/06 20:05
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, July 31, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to two new employees consisting of an aggregate o
GlobeNewswire · 07/31 20:08
Bellicum to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Management to host webcast and conference call on Thursday, August 6, 2020 at 5 p.m. ET / 2 p.m. PTHOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for
GlobeNewswire · 07/30 20:05
Bellicum Pharma on go with mid-stage study of BPX-603 for HER2+ solid tumors
Seeking Alpha - Article · 06/15 12:52
Bellicum Pharma Reports FDA Investigational New Drug Clearance To Initiate Phase 1/2 Trial Of BPX-603 For HER2+ Solid Tumors
Benzinga · 06/15 11:35
Bellicum Receives FDA IND Clearance to Initiate a Phase 1/2 Clinical Trial for BPX-603, a Dual-Switch GoCAR-T® for HER2+ Solid Tumors
HOUSTON, June 15, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced.
GlobeNewswire · 06/15 11:30
Here is What Hedge Funds Think About Bellicum Pharmaceuticals Inc (BLCM)
In this article you are going to find out whether hedge funds think Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there h
Insider Monkey · 06/12 14:44
Bellicum Pharmaceuticals Says M.D. Anderson To Resume, On Phased Basis, Selected Research, Manufacturing Activities
M.D. Anderson Manufacturing Activities   The University of Texas M.D. Anderson Cancer Center (“M.D. Anderson”) notified Bellicum Pharmaceuticals, Inc. (the “Company”) of its decision to
Benzinga · 06/03 10:17
Top Ranked Momentum Stocks to Buy for June 1st
Top Ranked Momentum Stocks to Buy for June 1st
Zacks · 06/01 14:45
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The Compensation Committee of the Board of Directors approved the grants with an effective date of May 29, 2020. The stock options were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listin
GlobeNewswire · 05/29 20:06
Bellicum Announces Publication of Data for GoCAR-NK™ Cell Program
HOUSTON, May 27, 2020 -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the.
GlobeNewswire · 05/27 20:05
Bellicum to Participate in Two Upcoming Virtual Investor Conferences
GlobeNewswire · 05/27 12:30
All You Need to Know About Bellicum Pharmaceuticals (BLCM) Rating Upgrade to Strong Buy
Bellicum Pharmaceuticals (BLCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
Zacks · 05/22 16:00
96 Biggest Movers From Friday
Gainers Fuel Tech, Inc (NASDAQ: FTEK) shares climbed 93.6% to close at $0.91 on Friday after the company reported FUEL CHEM® demonstration orders from two new industrial power customers.
Benzinga · 05/11 09:14
AAOI, HEAR, RIOT and BLCM among midday movers
Seeking Alpha - Article · 05/08 16:44
Bellicum Pharmaceuticals Q1 EPS $1.090 May Not Compare To $(0.550) YoY
Bellicum Pharmaceuticals (NASDAQ:BLCM) reported quarterly earnings of $1.090 per share. This is a 298.18 percent increase over losses of $(0.550) per share from the same period last year.
Benzinga · 05/07 20:45
Bellicum Reports First Quarter 2020 Financial Results and Provides Operational Update  
Bellicum’s three GoCAR™ programs remain on track Completed $15 million sale of manufacturing, office and laboratory facility to MD Anderson and entered into supply agreement.
GlobeNewswire · 05/07 20:05